Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Status and phase: Unknown; Phase 1

Conditions: GnRHa;LPS

Treatments: Drug: Gonadotrophin releasing hormone agonist(GnRHa)

Study type: Interventional

Funder types: Other

Identifiers

NCT02908438

ART-GnRHa for LPS

Details and patient eligibility

About

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.

Enrollment: 400 estimated patients

Sex: Female

Ages: 18 to 37 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age < 37 years;
2. One or more high quality embryos have been got in IVF/ICSI treatment;
3. To transfer at lest 2 fresh embryos;
4. Uterine endometrial thickness ≥ 7mm;
5. Patients have signed informed consents.

Exclusion criteria

1. ≥3 IVF/ICSI/FET cycles and no pregnancy;
2. Polycystic ovary syndrome(PCOS);
3. uterine malformation;
4. endometriosis
5. patients with a history of recurrent pregnancy loss.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

400 participants in 2 patient groups

GnRHa group

Experimental group

Description:

Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

Treatment:

Drug: Gonadotrophin releasing hormone agonist(GnRHa)

control group

No Intervention group

Description:

Control group receive only the routine LPS.